CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$46.74 USD
-1.44 (-2.99%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $46.77 +0.03 (0.06%) 6:26 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for CRISPR Therapeutics AG falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 371 | 1 | 915 | 1 | 290 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 371 | 1 | 915 | 1 | 290 |
Selling & Adminstrative & Depr. & Amort Expenses | 594 | 674 | 541 | 355 | 243 |
Income After Depreciation & Amortization | -223 | -673 | 374 | -354 | 47 |
Non-Operating Income | 72 | 23 | 6 | 6 | 21 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -151 | -651 | 380 | -348 | 67 |
Income Taxes | 3 | 0 | 2 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -154 | -650 | 378 | -349 | 67 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -154 | -650 | 378 | -349 | 67 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -203 | -649 | 406 | -345 | 51 |
Depreciation & Amortization (Cash Flow) | 20 | 24 | 32 | 9 | 5 |
Income After Depreciation & Amortization | -223 | -673 | 374 | -354 | 47 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 79.22 | 77.75 | 80.39 | 65.95 | 56.93 |
Diluted EPS Before Non-Recurring Items | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 |
Diluted Net EPS (GAAP) | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 |
Fiscal Year end for CRISPR Therapeutics AG falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.52 | 0.50 | 201.21 | 0.00 | 70.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.52 | 0.50 | 201.21 | 0.00 | 70.00 |
SG&A, R&D, and Dept/Amort Expenses | 151.78 | 141.09 | 131.62 | 132.41 | 165.23 |
Income After SG&A, R&D, and Dept/Amort Expenses | -151.26 | -140.59 | 69.59 | -132.41 | -95.23 |
Non-Operating Income | 26.14 | 24.72 | 20.00 | 20.67 | 18.41 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -125.12 | -115.87 | 89.58 | -111.74 | -76.82 |
Income Taxes | 1.29 | 0.72 | 0.23 | 0.41 | 0.92 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -126.41 | -116.59 | 89.35 | -112.15 | -77.74 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -126.41 | -116.59 | 89.35 | -112.15 | -77.74 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 84.92 | 81.80 | 81.33 | 79.41 | 79.09 |
Diluted EPS Before Non-Recurring Items | -1.49 | -1.43 | 1.10 | -1.41 | -0.98 |
Diluted Net EPS (GAAP) | -1.49 | -1.43 | 1.12 | -1.41 | -0.98 |